article thumbnail

Indian healthcare providers and pharma companies speed up to combat TB as drug resistance concerns emerge

AuroBlog - Aurous Healthcare Clinical Trials blog

Indian healthcare providers and pharma companies pace up their efforts with early detection and research for new medicines to combat the spread of tuberculosis as drug resistance concerns emerge. TB is a significant public health threat, with an estimated 10 million annual cases. India shares the highest TB burden with 2.69

article thumbnail

Thrust on R&D to develop better medicines & demand for technologies driven by AI transforming patient care

AuroBlog - Aurous Healthcare Clinical Trials blog

The pharma companies’ thrust on R&D to develop better medicines and the demand in hospitals for advanced medical technologies driven by artificial intelligence, remote patient monitoring and wearables are transforming patient care.

Medicine 150
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The largest pharma company in Europe calls for interoperability

pharmaphorum

Data is readily shared and leveraged for decision-makers to gain insight that can help clinical research. Jessica Hagen is a freelance life sciences and health writer and project manager who has worked with VR health companies, fiction/nonfiction authors, nonprofit and for-profit organisations, and government entities.

article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The overhaul will address drug marketing exclusivity length, pricing, patient access, innovation incentives, antimicrobial resistance, clinical trials, supply chain security and shortages, and environmental impact. EU competitiveness Moll said the legislation revisions should instead be used to make Europe more attractive to pharma companies.

article thumbnail

Can technology help diversify clinical trials?

pharmaphorum

This is the second in a two-part series examining how pharma can embrace the DEI agenda to create more effective medicines through more representative clinical trials. There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials. What comes next?

article thumbnail

EMA pilot will see if clinical trial data should be digested ‘raw’

pharmaphorum

The EMA is looking for pharma companies that are about to submit marketing applications for products to participate in the pilot, which is expected to last two years and cover up to ten regulatory submissions.

article thumbnail

Team behind RECOVERY trial of COVID drugs casts its net wider

pharmaphorum

The UK scientists that ran one of the largest trials of experimental COVID-19 drugs have formed a non-profit company that will apply the methodology to other disease areas – with $6.8 million in funding from French drugmaker Sanofi.

Trials 97